AbbVie's upadacitinib meets in third Phase III for RA

AbbVie Inc. (NYSE: ABBV) said both doses of oral upadacitinib (ABT-494) met the primary endpoints in the Phase III SELECT-MONOTHERAPY trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to methotrexate. Upadacitinib is an

Read the full 402 word article

User Sign In